| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/27/2010 | EP2147310A2 Compositions and methods for inhibiting g protein signaling |
| 01/27/2010 | EP2147122A1 Enzymatic anticancer therapy |
| 01/27/2010 | EP2147096A2 Modified factor vii polypetides and uses thereof |
| 01/27/2010 | EP2147018A1 Y-receptor agonists |
| 01/27/2010 | EP2147015A2 Mutants of cholesterol-dependent cytolysins and uses thereof |
| 01/27/2010 | EP2146753A2 18f fluoro-benzoyl labelled biological active compounds as diagnostic imaging agents as well as benzotriazol-1-yloxy-benzoyl , 2,5-dioxo-pyrrolidin-1-yloxy)benzoyl and trimethylammonio-benzoyl precursers thereof |
| 01/27/2010 | EP2146750A1 Stabilized suspension |
| 01/27/2010 | EP2146741A2 Medicaments and methods to treat autoimmune disease and cancer |
| 01/27/2010 | EP2146740A1 Methods of controlling tumorigenesis and diagnosing the risk thereof |
| 01/27/2010 | EP2146739A2 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 01/27/2010 | EP2146738A2 Wound healing compositions containing keratin biomaterials |
| 01/27/2010 | EP2146737A1 Copolymer synthesized from modified glycosaminoglycan, gag, and an anhydride functionalized hydrophobic polymer |
| 01/27/2010 | EP2146736A2 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 01/27/2010 | EP2146735A1 Sparc and methods of use thereof |
| 01/27/2010 | EP2146734A2 Novel peptide amphiphiles having improved solubility and methods of using same |
| 01/27/2010 | EP2146733A2 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| 01/27/2010 | EP2146727A1 High viscosity macromolecular compositions for treating ocular conditions |
| 01/27/2010 | EP2146723A1 Means and methods for counteracting protein aggregation |
| 01/27/2010 | EP2146695A2 Pharmaceutical compositions |
| 01/27/2010 | EP2146694A1 Formulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics |
| 01/27/2010 | EP1704227B1 Immortalized hepatocytes |
| 01/27/2010 | EP1692186B1 Cancer cell targeting gene delivery method |
| 01/27/2010 | EP1362106B1 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 01/27/2010 | EP1234875B1 Novel metalloprotease having aggrecanase activity |
| 01/27/2010 | EP1206563B1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 01/27/2010 | CN101636175A Biomarkers for neurological conditions |
| 01/27/2010 | CN101636174A Tumor vaccine, a method for producing a tumor vaccine and a method for carrying out antitumor immunotherapy |
| 01/27/2010 | CN101633692A Methods for making apo-2 ligand using divalent metal ions |
| 01/27/2010 | CN101633689A Peptide selection method |
| 01/27/2010 | CN101633636A Peptidomimetic protease inhibitors |
| 01/27/2010 | CN101632832A Component for reducing body fat formation and application thereof |
| 01/27/2010 | CN100584948C Procine circoviruses, vaccines and diagnostic reagents |
| 01/27/2010 | CN100584945C Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 01/27/2010 | CN100584944C Trimeresurus albolabris defibrase preparation method |
| 01/27/2010 | CN100584860C A plurality of reconstructing antibiotic peptide and preparation method and application thereof |
| 01/27/2010 | CN100584859C Process for the preparation of echinocandin derivatives |
| 01/27/2010 | CN100584858C RA antigenic peptides |
| 01/27/2010 | CN100584379C Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| 01/27/2010 | CN100584376C Medicine for treating deep erosive trauma with crust |
| 01/27/2010 | CN100584375C Formula for treating scar |
| 01/27/2010 | CN100584343C Medicine health-care usage of globefish I collagen extraction and preparing process thereof |
| 01/27/2010 | CN100584325C Medicine composition containing sodium azulene sulfonate and L-glutamine water-soluble precursor |
| 01/27/2010 | CN100584324C Use of camostat in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) |
| 01/27/2010 | CN100584314C Composition having gelling properties for the prolonged delivery of bioactive substances |
| 01/26/2010 | US7653495 Comprises series of steps including identifying cavity proximal to functional critical site, determining physical parameters of cavity, identifying functional groups which can be accommodated by cavity, testing compounds comprising such functional groups in an in vitro assay to determine which are active |
| 01/26/2010 | US7652153 Caspase inhibitors and uses thereof |
| 01/26/2010 | US7652069 Polymorphs of suberoylanilide hydroxamic acid |
| 01/26/2010 | US7652060 Small molecule rotamase enzyme inhibitors |
| 01/26/2010 | US7652025 Remedies for sepsis |
| 01/26/2010 | US7651998 administering a Venezuelan Equine Encephalitis (VEE) vector (alpha virus vector) comprising a heterologus nucleotide sequence to a subject; concurrently administering an antibody that specifically binds to the E1 and/or the E2 glycoprotein of the VEE vector to produce immune response to cancer patient |
| 01/26/2010 | US7651997 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them |
| 01/26/2010 | US7651996 1 wt.% insulin, 2 wt. % oxacyclohexadecane-2-one as permeation enhancer, 1% wt. cottenseed oil, 0.6 wt.% Sorbitan, 0.7 wt. % Polysorbate 20, 94.3 wt. % water, buffer amounts of 0.3 wt. % citric acid (monohydrate) and 0.1 wt. % sodium citrate (dihydrate); nasal drug delivery |
| 01/26/2010 | US7651995 Absorption enhancers such as e.g. BHT, BHA or propyl gallate |
| 01/26/2010 | US7651857 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 01/26/2010 | US7651849 Increased activity and stability at increased pH and temperature |
| 01/26/2010 | US7651845 Combined control of insulin bolus dosing and basal delivery for the goal of achieving normal glycemic response to meals, exercise, stressors, and other perturbations to blood glucose levels |
| 01/26/2010 | US7651703 Comprising hyaluronic acid or sodium hyaluronate dissolved in physiological buffer at concentration of 0.01-3 percent weight per volume and particles comprising first component biologically active agent and second component biocompatible polymeric matrix; use of 23-gauge or smaller bore needle |
| 01/26/2010 | US7651699 Autoinducer compounds and their uses |
| 01/26/2010 | US7651694 Encapsulated with macromolecules, bile salts |
| 01/26/2010 | US7651656 Melting furnace with agitator and agitator for melting furnace |
| 01/26/2010 | CA2499354C Transcription control factor zhx3 |
| 01/26/2010 | CA2493534C Pegylated t20 polypeptide |
| 01/26/2010 | CA2434731C Modular infusion device and method |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2421588C Tnf receptor-like molecules and uses thereof |
| 01/26/2010 | CA2404237C Methods of investigating, diagnosing, and treating amyloidosis |
| 01/26/2010 | CA2309907C Method for inducing osteoblast differentiation of human extramedullary adipose tissue cells |
| 01/26/2010 | CA2301499C T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof |
| 01/26/2010 | CA2301175C Collagen mimics |
| 01/26/2010 | CA2230086C Method to improve the biological and antiviral activity of protease inhibitors |
| 01/26/2010 | CA2222524C Somatostatin peptides |
| 01/26/2010 | CA2213500C Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 01/26/2010 | CA2213301C Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) |
| 01/26/2010 | CA2201841C Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| 01/26/2010 | CA2188817C Angiogenesis inhibitor |
| 01/21/2010 | WO2010009456A1 Mycobacterium tuberculosis rv3671c gene encoded membrane protease as a target for inhibitors of intrabacterial ph homeostasis and acid resistance |
| 01/21/2010 | WO2010009403A2 Methods for treating arthritis and other inflammatory or autoimmune diseases |
| 01/21/2010 | WO2010009380A2 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome |
| 01/21/2010 | WO2010009312A2 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |
| 01/21/2010 | WO2010009227A2 Recombinant pokeweed antiviral proteins, compositions and methods related thereto |
| 01/21/2010 | WO2010009190A1 Methods of treating atherosclerosis |
| 01/21/2010 | WO2010008995A2 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| 01/21/2010 | WO2010008792A1 Nanoparticles for use as synthetic platelets and therapeutic agent delivery vehicles |
| 01/21/2010 | WO2010008573A2 Wound healing |
| 01/21/2010 | WO2010008561A2 Methods and compositions for protecting against cytotoxic therapy |
| 01/21/2010 | WO2010008436A1 Methods and compositions for inhibition of bcl6 repression |
| 01/21/2010 | WO2010008084A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | WO2010008023A1 Bone elongation promoter |
| 01/21/2010 | WO2010007724A1 Peptide capable of binding to epcam |
| 01/21/2010 | WO2010007701A1 Therapeutic agent and test agent for disease with myocardial necrosis |
| 01/21/2010 | WO2010007622A2 Long-acting interferons and derivatives thereof and methods thereof |
| 01/21/2010 | WO2010007551A2 Method for the production of tenocytes in vitro from mesenchymal stem cells |
| 01/21/2010 | WO2010007531A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia |
| 01/21/2010 | WO2010007494A2 New composition for the treatment of ecchymotic pigmentations |
| 01/21/2010 | WO2010007464A1 USE OF DEFENSIN α1 AND/OR DEFENSIN α4, AS A MARKER FOR PREDICTING A RELAPSE IN A PATIENT SUFFERING FROM CHRONIC MYELOID LEUKAEMIA |
| 01/21/2010 | WO2010007381A1 Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| 01/21/2010 | WO2010007353A1 Catabolic agents |
| 01/21/2010 | WO2010007250A1 D,d-muramyl dipeptides, derived compounds and use thereof for the treatment of atheromatous plaques |
| 01/21/2010 | WO2010007176A1 Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders |
| 01/21/2010 | WO2010007175A2 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |